Search
Now showing items 1-4 of 4
Cladribine: Off-label disease modification for people with multiple sclerosis in resource-poor settings?
(2018-04)
Background: A considerable number of people with multiple sclerosis (pwMS) live in low- and middle-income countries (LMIC), where lack of resource adversely affects access to effective disease-modifying treatment. Objective: ...
Alemtuzumab depletion failure can occur in multiple sclerosis.
(2018-06)
Alemtuzumab is a lymphocyte-depleting antibody and one of the most effective treatments for relapsing multiple sclerosis. However, it also causes loss of immune-tolerance leading to secondary autoimmunity and marked anti-drug ...
Disease activity 4.5 years after starting cladribine: experience in 264 patients with multiple sclerosis.
(2023)
BACKGROUND: Cladribine is an effective immunotherapy for people with multiple sclerosis (pwMS). Whilst most pwMS do not require re-treatment following standard dosing (two treatment courses), disease activity re-emerges ...